Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 12:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CF Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2

NCT02447783
View directory record Official record
Conditions
Healthy
Interventions
Control Capsules, Mars Cocoa Extract Capsules
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Not applicable Interventional

Clinical Effort Against Smoke Exposure in Cystic Fibrosis

NCT04777344
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobacco Treatment Specialist (TTS) intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

NCT02054156
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo, Tobramycin solution for inhalation
Drug
Lead sponsor
Bonnie Ramsey
Other
Eligibility
6 Months to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 8, 2026, 12:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

NCT03784963
View directory record Official record
Conditions
Heart Failure, Gastrointestinal Bleeding
Interventions
Omega 3 fatty acids, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

NCT03375047
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MRT5005, Normal saline
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
16
States / cities
Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 8, 2026, 12:10 AM EDT
Completed No phase listed Observational

Immune Profiles in CF Fungal Infection

NCT04476758
View directory record Official record
Conditions
Cystic Fibrosis, Fungal Infection, Allergic Bronchopulmonary Aspergillosis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 25 Years
Enrollment
24 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 8, 2026, 12:10 AM EDT
Completed No phase listed Observational

Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF

NCT01832519
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 52 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 8, 2026, 12:10 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines

NCT03526107
View directory record Official record
Conditions
Healthy
Interventions
CF Control, CF-Theobromine, CF-Caffeine
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 8, 2026, 12:10 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

NCT02498535
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide 160 ppm
Drug
Lead sponsor
Novoteris, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 8, 2026, 12:10 AM EDT
Not listed Phase 2 Interventional

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

NCT02724527
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cavosonstat, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 8, 2026, 12:10 AM EDT
Terminated Early Phase 1 Interventional

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

NCT03497117
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung Clearance Index, MRI with PFP
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 8, 2026, 12:10 AM EDT
Not listed Phase 1Phase 2 Interventional

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

NCT02210468
View directory record Official record
Conditions
Pain, Osteoarthritis
Interventions
APIC-CF, 4 cc, APIC-CF, 2 cc, Placebo Comparator: Saline
Device · Other
Lead sponsor
Cytonics Corporation
Industry
Eligibility
21 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Townsend, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Not applicable Interventional

Effects of a Partially Supervised Conditioning Program in CF

NCT01744561
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Wuerzburg University Hospital
Other
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 2 Interventional

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

NCT01695343
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
KB001-A, Placebo Comparator
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 8, 2026, 12:10 AM EDT
Terminated Phase 3 Interventional Results available

Prevention of Cystic Fibrosis Diabetes

NCT00967798
View directory record Official record
Conditions
Cystic Fibrosis, Prediabetes
Interventions
Sitagliptin
Drug
Lead sponsor
Emory University
Other
Eligibility
13 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 8, 2026, 12:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

NCT02323100
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ravicti low dose, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

NCT04058353
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA, TEZ/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Not applicable Interventional Results available

Behavioral & Nutritional Treatment to Help CF Preschoolers Grow

NCT00241969
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Cystic Fibrosis
Interventions
Behavioral and Nutrition Treatment, Education and Attention Control
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 8, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT01173601
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Irvine, California • La Habra, California • Redlands, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 8, 2026, 12:10 AM EDT